Home › Research › Getting a diagnosis
Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, et al.. Alzheimer's & Dementia, 2025-07-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The panel cautions users of this guideline that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds, especially using a single cutoff.
What this study adds
Evidence grade: High
This is a pooled review. This clinical practice guideline cautions that there is significant variability in the accuracy of blood-based biomarker tests for Alzheimer's disease. Its stated limit: Applies only to specialist settings and symptomatic patients; the underlying evidence was rated moderate to very low certainty; test performance varies by assay and single cut-offs; a living update process is planned.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Palmqvist, S., Whitson, H. E., Allen, L. A., Suarez-Calvet, M., Galasko, D., Karikari, T. K., et al. (2025). Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70535
Vancouver
Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70535. PMID: 40729527.
BibTeX
@article{palmqvist2025-40729527,
author = {Palmqvist, S. and Whitson, H. E. and Allen, L. A. and Suarez-Calvet, M. and Galasko, D. and Karikari, T. K. and Okrahvi, H. R. and Paczynski, M. and Schindler, S. E. and Teunissen, C. E. and others},
title = {{Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings}},
journal = {Alzheimer's \& Dementia},
year = {2025},
doi = {10.1002/alz.70535},
pmid = {40729527},
url = {https://doi.org/10.1002/alz.70535}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The panel cautions users of this guideline that there is significant variability in diagnostic test accuracy and many commercially available BBM tests do not meet these thresholds, especially using a single cutoff.
Why it matters
This clinical practice guideline cautions that there is significant variability in the accuracy of blood-based biomarker tests for Alzheimer's disease. It notes that many commercially available tests do not meet the guideline's thresholds, especially when using a single cutoff.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designsystematic-review
- Evidence strengthHigh
Limitations
Applies only to specialist settings and symptomatic patients; the underlying evidence was rated moderate to very low certainty; test performance varies by assay and single cut-offs; a living update process is planned.
How this study scored 73/100
Published in a leading specialty journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on free to read, so that was left out: it earned 72 of the 98 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 169 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 56.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 6 / 6 | Cited 107.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 20 other studies in this library |
| Still being cited | 3 / 4 | Cited 169 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Malavika P. Tampi: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 19 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40729527) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 72 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 72 of the 98 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 31.
Later studies that cite this one
20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also in Getting a diagnosis
141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.